High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry

Marques, Claudia Diniz Lopes; Kakehasi, Adriana Maria; Pinheiro, Marcelo Medeiros; Mota, Licia Maria Henrique; Albuquerque, Cleandro Pires; Silva, Carolina Rocha; Santos, Gabriela Porfirio Jardim; Reis-Neto, Edgard Torres; Matos, Pedro; Devide, Guilherme; Dantas, Andrea; Giorgi, Rina Dalva; Marinho, Adriana de Oliveira; Valadares, Lilian David Azevedo; Melo, Ana Karla G; Ribeiro, Francinne Machado; Ferreira, Gilda Aparecida; Santos, Flavia Patricia de Sena; Ribeiro, Sandra Lucia Euzebio; Andrade, Nicole Pamplona Bueno; Yazbek, Michel Alexandre; de Souza, Viviane Angelina; Paiva, Eduardo S; Azevedo, Valderilio Feijo; de Freitas, Ana Beatriz Santos Bacchiega; Provenza, José Roberto; de Toledo, Ricardo Acayaba; Fontenelle, Sheilla; Carneiro, Sueli; Xavier, Ricardo; Pileggi, Gecilmara Cristina Salviato; Reis, Ana Paula Monteiro Gomides

OBJECTIVES: To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. METHODS: Analysis of the first 8 weeks of observational multicentre prospective cohort study (ReumaCoV Brasil register). Patients with IMRD and COVID-19 according to the Ministry of Health criteria were classified as eligible for the study. RESULTS: 334 participants were enrolled, a majority of them women, with a median age of 45 years; systemic lupus erythematosus (32.9%) was the most frequent IMRD. Emergency care was required in 160 patients, 33.0% were hospitalised, 15.0% were admitted to the ICU and 10.5% underwent mechanical ventilation; 28 patients (8.4%) died. In the multivariate adjustment model for emergency care, diabetes (prevalence ratio, PR 1.38; 95% CI 1.11 to 1.73; p=0.004), kidney disease (PR 1.36; 95% CI 1.05 to 1.77; p=0.020), oral glucocorticoids (GC) (PR 1.49; 95% CI 1.21 to 1.85; p<0.001) and pulse therapy with methylprednisolone (PR 1.38; 95% CI 1.14 to 1.67; p=0.001) remained significant; for hospitalisation, age >50 years (PR 1.89; 95% CI 1.26 to 2.85; p=0.002), no use of tumour necrosis factor inhibitor (TNFi) (PR 2.51;95% CI 1.16 to 5.45; p=0.004) and methylprednisolone pulse therapy (PR 2.50; 95% CI 1.59 to 3.92; p<0.001); for ICU admission, oral GC (PR 2.24; 95% CI 1.36 to 3.71; p<0.001) and pulse therapy with methylprednisolone (PR 1.65; 95% CI 1.00 to 2.68; p<0.043); the two variables associated with death were pulse therapy with methylprednisolone or cyclophosphamide (PR 2.86; 95% CI 1.59 to 5.14; p<0.018). CONCLUSIONS: Age >50 years and immunosuppression with GC and cyclophosphamide were associated with unfavourable outcomes of COVID-19. Treatment with TNFi may have been protective, perhaps leading to the COVID-19 inflammatory process.